1 study found for:    lymphoma [CONDITION] OR CLL [CONDITION] | Open Studies | tru-016
Show Display Options
Rank Status Study
1 Recruiting Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab or Obinutuzumab in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab;   Biological: 10 mg/kg TRU-016 + Rituximab;   Biological: TRU-016 20 mg/kg + Obinutuzumab

Indicates status has not been verified in more than two years